行情

SRNE

SRNE

Sorrento Thera
NASDAQ

实时行情|Nasdaq Last Sale

2.480
+0.460
+22.77%
盘后: 2.380 -0.1 -4.03% 19:27 04/03 EDT
开盘
1.970
昨收
2.020
最高
2.680
最低
1.970
成交量
2,787.84万
成交额
--
52周最高
5.09
52周最低
1.390
市值
4.50亿
市盈率(TTM)
-1.1051
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SRNE价格均价为22.50,最高价位24.00,最低价为21.00。

EPS

SRNE 新闻

更多
  • NRZ, TWO, SRNE and CNX among midday movers
  • Seeking Alpha - Article · 1天前
  • SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS
  • GlobeNewswire · 2天前
  • Analyst Impressed by Sorrentos COVID-19 Pipeline, Says Buy
  • TipRanks · 3天前
  • Sorrento to test COVID-19 candidates in infection cell model with live virus
  • seekingalpha · 3天前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

SRNE 简况

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
展开

微牛提供Sorrento Therapeutics Inc(NASDAQ-SRNE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SRNE股票新闻,以帮助您做出投资决策。